Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-25T15:08:35.470Z Has data issue: false hasContentIssue false
  • English
  • Français

Vocal fold paralysis following first dose of Oxford-AstraZeneca coronavirus disease 2019 vaccine

Part of: JLO Coronavirus Collection

Published online by Cambridge University Press:  28 February 2022

G M Jama Open the ORCID record for G M Jama [Opens in a new window] ,
M Amin ,
A Hassaan  and
H Kaddour
G M Jama*
Affiliation:
Department of Otolaryngology, Queen's Hospital, Romford, UK
M Amin
Affiliation:
Department of Otolaryngology, Queen's Hospital, Romford, UK
A Hassaan
Affiliation:
Department of Otolaryngology, Queen's Hospital, Romford, UK
H Kaddour
Affiliation:
Department of Otolaryngology, Queen's Hospital, Romford, UK
*
Author for correspondence: Mr Guled M Jama, Department of Otolaryngology, Barking, Havering and Redbridge University Hospitals NHS Trust, Queen's Hospital, Rom Valley Way, RomfordRM7 0AG, UK E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

In a bid to end the ongoing coronavirus disease 2019 pandemic, many countries, including the UK, have rolled out mass immunisation programmes. While considered generally safe and effective, vaccines against coronavirus disease 2019 have been reported to be associated with rare and potentially adverse reactions and side effects.

Case report

This paper reports an unusual case of a patient who developed a unilateral vocal fold paralysis shortly after receiving the first dose of the Oxford-AstraZeneca ChAdOx1 nCov-19 vaccine.

Conclusion

To our knowledge, this is the first reported case of vocal fold paralysis following administration of the Oxford-AstraZeneca vaccine. The authors support the position that currently approved coronavirus disease 2019 vaccines remain safe and effective; however, further surveillance and vigilance using real-world data are highly encouraged.

Keywords

Vocal Cord ParalysisDysphoniaCOVID-19ImmunizationVaccinesDrug Side Effects
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 136 , Issue 5 , May 2022 , pp. 466 - 468
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Mr G M Jama takes responsibility for the integrity of the content of the paper

References

World Health Organization. WHO Coronavirus (COVID-19) Dashboard. In: https://covid19.who.int/ [27 May 2021]Google Scholar
Gov.uk. COVID-19 vaccination: information for healthcare practitioners. In: https://www.gov.uk/government/publications/covid-19-vaccination-programme-guidance-for-healthcare-practitioners [27 May 2021]Google Scholar
Lopez Bernal, J, Andrews, N, Gower, C, Robertson, C, Stowe, J, Tessier, E et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088CrossRefGoogle ScholarPubMed
Haas, EJ, Angulo, FJ, McLaughlin, JM, Anis, E, Singer, SR, Khan, F et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819–29CrossRefGoogle ScholarPubMed
Yellow Card Vaccine Monitor, Medicines and Healthcare products Regulatory Agency. In: https://vaccinemonitor-yellowcard.mhra.gov.uk/ [27 May 2021]Google Scholar
Menni, C, Klaser, K, May, A, Polidori, L, Capdevila, J, Louca, P et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021;21:939–49CrossRefGoogle ScholarPubMed
Østergaard, SD, Schmidt, M, Horváth-Puhó, E, Thomsen, RW, Sørensen, HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet 2021;397:1441–3CrossRefGoogle ScholarPubMed
Rosenthal, LH, Benninger, MS, Deeb, RH. Vocal fold immobility: a longitudinal analysis of etiology over 20 years. Laryngoscope 2007;117:1864–70CrossRefGoogle ScholarPubMed
Spataro, EA, Grindler, DJ, Paniello, RC. Etiology and time to presentation of unilateral vocal fold paralysis. Otolaryngol Head Neck Surg 2014;151:286–93CrossRefGoogle ScholarPubMed
Rees, CJ, Henderson, AH, Belafsky, PC. Postviral vagal neuropathy. Ann Otol Rhinol Laryngol 2009;118:247–52CrossRefGoogle ScholarPubMed
Amin, MR, Koufman, JA. Vagal neuropathy after upper respiratory infection: a viral etiology? Am J Otolaryngol 2001;22:251–6CrossRefGoogle ScholarPubMed
Talmor, G, Nguyen, B, Din-Lovinescu, C, Paskhover, B, Kaye, R. Vocal fold immobility following vaccination. Ann Otol Rhinol Laryngol 2021;130:609–13CrossRefGoogle ScholarPubMed
Patel, SU, Khurram, R, Lakhani, A, Quirk, B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep 2021;14:e242956CrossRefGoogle ScholarPubMed
Colella, G, Orlandi, M, Cirillo, N. Bell's palsy following COVID-19 vaccination. J Neurol 2021;268:3589–91CrossRefGoogle ScholarPubMed
Shemer, A, Pras, E, Hecht, I. Peripheral facial nerve palsy following BNT162b2 (COVID-19) vaccination. Isr Med Assoc J 2021;23:143–4Google ScholarPubMed
Repajic, M, Lai, XL, Xu, P, Liu, A. Bell's palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy. Brain Behav Immun Health 2021;13:100217CrossRefGoogle Scholar
Soeiro, T, Salvo, F, Pariente, A, Grandvuillemin, A, Jonville-Béra, AP, Micallef, J. Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy. Therapie 2021;76:365–7CrossRefGoogle ScholarPubMed
Folegatti, PM, Ewer, KJ, Aley, PK, Angus, B, Becker, S, Belij-Rammerstorfer, S et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467–78CrossRefGoogle Scholar
Greinacher, A, Thiele, T, Warkentin, TE, Weisser, K, Kyrle, PA, Eichinger, S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092–101CrossRefGoogle ScholarPubMed